Skip to content
Abzu logo
  • Platform
    • Hybrid AI
    • Transportation & logistics
    • Healthcare operations
  • Pharma R&D
    • Disease understanding
    • RNA therapeutics
    • Bioinformatics services
  • The QLattice®
    • Publications
  • About Abzu
    • Why Abzu
    • Meet the Abzoids
    • AI ethics
    • Careers
    • Scientific advisory board
    • Investors
  • News + media
    • Press releases
    • External media
    • Awards
    • Videos
    • Podcasts
  • Pricing
Menu
  • Platform
    • Hybrid AI
    • Transportation & logistics
    • Healthcare operations
  • Pharma R&D
    • Disease understanding
    • RNA therapeutics
    • Bioinformatics services
  • The QLattice®
    • Publications
  • About Abzu
    • Why Abzu
    • Meet the Abzoids
    • AI ethics
    • Careers
    • Scientific advisory board
    • Investors
  • News + media
    • Press releases
    • External media
    • Awards
    • Videos
    • Podcasts
  • Pricing
Contact us

Tag: RNA Therapeutics

Drug and target discovery with explainable AI.

Abzu video - Webinar - Drug and target discovery with explainable AI

Learn how explainable AI is enabling researchers to gain a deeper understanding of complex biological systems, uncover hidden patterns, and make more informed decisions.

SAE Media Group’s 14th Annual Conference – RNA Therapeutics.

Abzu event - 2023 - SAE RNA Therapeutics Conference

Investigating the next generation of genetic medicine through RNA-based therapies.

Oligonucleotide Therapeutics Society

Abzu speaks at the 18th annual Oligo Meeting

OTS is a forum to foster academic and industry-based research and development of oligonucleotide therapeutics.

Nordic Digital Science & Innovation Day

Abzu keynote at Nordic Digital Science & Innovation Day

Sharing the latest trends, innovations, and best practices for digitizing R&D assets to accelerate modern science.

Abzu increased safe lead candidates by 20% for top-10 pharmaceutical company.

Abzu increased safe lead candidates by 20% for an undisclosed top-10 pharmaceutical company.

siRNA molecule activity: explainable AI models uncover underlying mechanisms

Our results-driven world pressures us to give up good science.

Abzu® and Contera Pharma partner to design RNA therapeutics for rare diseases with explainable AI.

The two companies aim to have a rapid target screening application available this year, enabling Contera Pharma to advance better nucleic acid-based therapeutics towards clinic development.

AI and nucleic acid-based medicine: can symbolic regression unite them?

How the QLattice explains the cellular toxicity of RNA-targeting drugs.

Pharma services.

  • Disease understanding
  • RNA Therapeutics
  • Bioinformatics Services

Who we are.

  • Why Abzu
  • The QLattice®
  • Meet the Abzoids
  • Casper Wilstrup, CEO
  • Careers
  • The Abzu Handbook
  • Scientific advisory board
  • Investors

News + media.

  • Press releases
  • External media
  • Awards
  • Publications
  • Gartner® reports
  • Videos
  • Podcasts
  • Events

Contact Abzu.

  • Email a scientist.
  • Email sales.
  • Email Abzu.

© Abzu Aps. All rights reserved.
CVR DK39248530 | CIF B67165647

Terms + conditions

Privacy policy

Cookie-less policy

Security guide

LinkedIn
T
Instagram
Vimeo
YouTube
Medium
Discord
Spotify